付相玉,江致贤,严芝强,左石
FU Xiangyu,JIANG Zhixian,YAN Zhiqiang,ZUO Shi

• 1:贵州医科大学附属医院肝胆外科
• 2:贵州医科大学临床医学院
• 3:贵州医科大学胃肠外科

摘要(Abstract)：

目的 探讨术前系统免疫炎症指数(SII)、纤维蛋白原和白蛋白比值(FAR)对Child-PughA级肝细胞癌患者术后总生存期(OS)的预测价值。方法 收集接受手术治疗的121例肝细胞癌(HCC)患者的SII、FAR、实验室检查数据、临床病理和随访资料，采用受试者工作特征(ROC)曲线分析SII、FAR和其他临床指标的最佳截断值，并对患者进行分组；分析SII、FAR与患者临床病理特征之间的关联，利用单因素和多因素Cox回归分析明确影响HCC患者OS的独立危险因素、并构建列线图预测模型；使用C-指数、校准曲线和时间依赖的ROC曲线评估模型的诊断效能，并通过综合判别改善指数(IDI)、净重新分类指数(NRI)和决策曲线分析法(DCA)对模型预测能力进行评价。结果 ROC曲线显示SII的最佳截断值为362.876、患者分为高表达组(>362.876,n=56)和低表达组(≤362.876,n=65),FAR的最佳截断值为0.075、患者分为高表达组(≥0.075,n=69)和低表达组(<0.075,n=52);Kaplan-Meier分析显示，低SII组、低FAR组患者1、3、5年OS优于高SII组、高FAR组(P<0.005);单因素、多因素Cox回归分析结果显示，肿瘤最大直径、红细胞计数(RBC)、纤维蛋白原(Fg)、SII、FAR是影响HCC患者OS的独立危险因素(P<0.05),并构建列线图模型；列线图模型经内部验证后C-指数为0.696(0.551～0.841),预测1、3、5年OS的曲线下面积(AUCs)分别为0.739、0.744、0.776,并且校准曲线、NRI/IDI和DCA曲线提示模型在生存预后的预测上有一定的效能。结论 术前SII、FAR与Child-Pugh A级HCC患者的预后相关，高水平SII、FAR患者的预后较差。
Objective To investigate the prognostic value of preoperative systemic immune-inflammation index(SII) and fibrinogen-to-albumin-ratio(FAR) for the postoperative overall survival(OS) of patients with Child-Pugh grade A hepatocellular carcinoma(HCC). Methods SII, FAR, laboratory examination data, clinical pathology and follow-up data were collected from 121 patients with HCC who underwent surgery. Receiver operating characteristic(ROC) curve was used to analyze the optimal cutoff values for SII, FAR and other clinical indicators to group the patients. The associations of SII and FAR with clinical pathological characteristics of the patients were analyzed. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors affecting OS of the patients with HCC and construct a nomogram prediction model. The diagnostic performance of the model was evaluated using C-index, calibration curve and time-dependent ROC curve. The predictive ability of the model was assessed through integrated discrimination improvement(IDI), net reclassification index(NRI), and decision curve analysis(DCA). Results ROC curve showed that the optimal cut-off value for SII was 362.876, which was used to divide the patients into a high SII group(>362.876, n=56) and a low SII group(≤362.876, n=65). The best cut-off value for FAR was 0.075, which was used to divided the patients into a high FAR group(≥0.075, n= 69) and a low FAR group(<0.075, n= 52). Kaplan-Meier analysis showed that the low SII and low FAR groups had significantly better OS than the high SII and high FAR groups did(P<0.005). Univariate and multivariate Cox regression analyses showed that tumor maximum diameter, red blood cell count(RBC), fibrinogen(Fg), SII, and FAR were independent risk factors affecting OS of the patients with HCC(P<0.05). A nomogram was constructed. After internal validation for the nomogram, the C-index was 0.696(0.551–0.841), and the areas under the curve(AUCs) for predicting OS of 1, 3, and 5 years were 0.739, 0.744 and 0.776, respectively. The calibration curve, NRI/IDI, and DCA curves suggested that the model had certain effectiveness in predicting the survival. Conclusion Preoperative SII and FAR are correlated with the prognosis of patients with Child-Pugh grade A HCC. The patients with the high SII and FAR levels have poor prognosis.

关键词(KeyWords)： 肝细胞肿瘤;系统免疫炎症指数;纤维蛋白原/白蛋白比值;列线图;预后
hepatocellular carcinoma;systemic immune-inflammation index;fibrinogen-to-albumin ratio;nomogram;prognosis

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金地区项目(82260535)

作者(Author): 付相玉,江致贤,严芝强,左石
FU Xiangyu,JIANG Zhixian,YAN Zhiqiang,ZUO Shi

DOI: 10.19367/j.cnki.2096-8388.2024.07.012

参考文献(References)：

• [1] ZHENG Y,LI Y,FENG J,et al.Cellular based immunotherapy for primary liver cancer[J].J Exp Clin Cancer Res,2021,40(1):250.
• [2] YANG J D,HAINAUT P,GORES G J,et al.A global view of hepatocellular carcinoma:trends,risk,prevention and management[J].Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
• [3] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
• [4] RUMGAY H,ARNOLD M,FERLAY J,et al.Global burden of primary liver cancer in 2020 and predictions to 2040[J].J Hepatol,2022,77(6):1598-1606.
• [5] ALLAIRE M,GOUMARD C,LIM C,et al.New frontiers in liver resection for hepatocellular carcinoma[J].JHEP Rep,2020,2(4):100134.
• [6] ZHENG R,QU C,ZHANG S,et al.Liver cancer incidence and mortality in China:temporal trends and projections to 2030[J].Chin J Cancer Res,2018,30(6):571-579.
• [7] HU X,CHEN R,WEI Q,et al.The landscape of alpha fetoprotein in hepatocellular carcinoma:where are we[J].Int J Biol Sci,2022,18(2):536-551.
• [8]TANG Y,XU L,REN Y,et al.Identification and validation of a prognostic model based on three MVI-related genes in hepatocellular carcinoma[J].Int J Biol Sci,2022,18(1):261-275.
• [9]ZHANG B,WEI G,LI R,et al.N-3 fatty acid-based parenteral nutrition improves postoperative recovery for cirrhotic patients with liver cancer:a randomized controlled clinical trial[J].Clin Nutr,2017,36(5):1239-1244.
• [10]SANGRO B,MELERO I,WADHAWAN S,et al.Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma[J].J Hepatol,2020,73(6):1460-1469.
• [11]SUN J,ZHOU G,XIE X,et al.Efficacy and safety of drug-eluting beads transarterial chemoembolization by callispheres((r)) in 275 hepatocellular carcinoma patients:results from the chinese callispheres((r)) transarterial chemoembolization in liver cancer (CTILC) study[J].Oncol Res,2020,28(1):75-94.
• [12]YUAN Y,YANG F,WANG Y,et al.Factors associated with liver cancer prognosis after hepatectomy:a retrospective cohort study[J].Medicine (Baltimore),2021,100(42):e27378.
• [13]DU Q,WANG Y,GUAN S,et al.The diagnostic nomogram of platelet-based score models for hepatic alveolar echinococcosis and atypical liver cancer[J].Sci Rep,2019,9(1):19403.
• [14]LIU P H,HSU C Y,HSIA C Y,et al.Prognosis of hepatocellular carcinoma:assessment of eleven staging systems[J].J Hepatol,2016,64(3):601-628.
• [15]HIRAOKA A,KUMADA T,MICHITAKA K,et al.Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients[J].Liver Cancer,2019,8(5):312-325.
• [16]孙小凡，刘贵朋.外周血炎症指标与宫颈癌临床病理特征的相关性[J].中国医科大学学报，2022,51(7):627-632.
• [17]LAZENNEC G,RICHMOND A.Chemokines and chemokine receptors:new insights into cancer-related inflammation[J].Trends Mol Med,2010,16(3):133-144.
• [18]BALKWILL F,MANTOVANI A.Inflammation and cancer:back to Virchow?[J].Lancet,2001,357(9255):539-545.
• [19]DIAKOS C I,CHARLES K A,MCMILLAN D C,et al.Cancer-related inflammation and treatment effectiveness[J].Lancet Oncol,2014,15(11):e493-503.
• [20]SOHRAB S S,RAJ R,NAGAR A,et al.Chronic inflammation's transformation to cancer:a nanotherapeutic paradigm[J].Molecules,2023,28(11):.
• [21]LIU D,HEIJ L R,CZIGANY Z,et al.The role of tumor-infiltrating lymphocytes in cholangiocarcinoma[J].J Exp Clin Cancer Res,2022,41(1):127.
• [22]ZHENG X,JIN W,WANG S,et al.Progression on the roles and mechanisms of tumor-infiltrating T lymphocytes in patients with hepatocellular carcinoma[J].Front Immunol,2021,12:729705.
• [23]SCHLESINGER M.Role of platelets and platelet receptors in cancer metastasis[J].J Hematol Oncol,2018,11(1):125.
• [24]PAULSEN B,SKILLE H,SMITH E N,et al.Fibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolism[J].Haematologica,2020,105(7):1963-1968.
• [25]MADEDDU C,GRAMIGNANO G,ASTARA G,et al.Pathogenesis and treatment options of cancer related anemia:perspective for a targeted mechanism-based approach[J].Front Physiol,2018,(1294):1-20.
• [26]WANG L,LI Q,ZHANG J,et al.A novel prognostic scoring model based on albumin and gamma-glutamyltransferase for hepatocellular carcinoma prognosis[J].Cancer Manag Res,2019,11:10685-10694.
• [27]JOHNSON P J,BERHANE S,KAGEBAYASHI C,et al.Assessment of liver function in patients with hepatocellular carcinoma:a new evidence-based approach-the ALBI grade[J].J Clin Oncol,2015,33(6):550-558.
• [28]刘卓然，黎靖，周宇，等.基于HALP评分的列线图模型对肝细胞癌患者肝切除术后预后的预测价值[J].临床肝胆病杂志，2023,39(7):1600-1608.
• [29]SCHOBERT I T,SAVIC L J,CHAPIRO J,et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE[J].European Radiology,2020,30(10):5663-5673.

文章评论(Comment)：